Navigation Links
Lilly Declares Third-Quarter Dividend
Date:6/22/2009

INDIANAPOLIS, June 22 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the third quarter of 2009 of $0.49 a share on outstanding common stock. This is the same dividend as was paid in the first and second quarters and maintains the annual indicated dividend rate for 2009 of $1.96 per share.

The dividend is payable September 10, 2009, to shareholders of record at the close of business on August 15, 2009.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. F-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimers Disease Market
2. Eli Lilly and Company Announces New Drug Discovery Initiative
3. NAACP & Nine Class Reps File Motion for Class Certification Against Eli Lilly in Pervasive Discrimination Case
4. ICON Selected to Manage Lilly Clinical Trial Site Set Up and Monitoring in Europe
5. Bart Peterson to Join Lilly Leadership Team
6. Lilly Resubmits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
7. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
8. Covance Recognized for Outstanding Customer Service by Eli Lilly and Company
9. Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management
10. Lilly to Celebrate Second Annual Global Day of Service May 20
11. Lilly Chairman & CEO Lechleiter Says Innovation Is Vital-But-Missing Plank in Health Reform Debate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... ... The John P. McGovern Museum of Health and Medical Science is now partnered ... and share results with their physicians. Members and guests can sign up for its ... founder, Dr. David Eagleman, formerly at Baylor College of Medicine and now at Stanford ...
(Date:4/24/2017)... Waycross, Ga. (PRWEB) , ... April 24, 2017 ... ... and trusted advisor within the telehealth industry, announces the company’s VideoMedicine mobile platform ... primary care providers. Available 24 hours a day, Quick Care provides patients with ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... to recognize elevated anxiety levels in people with addiction who are served by ... Patch, a biosensing wearable device that monitors heart and breath rates to identify ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) Tampa ... Walter Blvd, for an educational and exciting 2-day program. , An attendee at ... this before they approach patients” about the course entitled Ain't Misbehavin': Decreasing and Managing ...
(Date:4/24/2017)... ... ... “Reflections of God’s Work”: an enlightening collection of life lessons leading each ... published author, Jerri Broglin, a survivor of great loss who gained insight on how ... for those searching for answers, as we are finding the answers that are so ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray product ... a healthy CAGR during the forecast period Mobile ... the global digital mobile X-Ray devices market, which is estimated ... 2017, expanding at a CAGR of 7% over the forecast ... opportunity of more than US$ 100 Mn in 2017 over ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology: